DeekSeek founder hailed as hero, copycat investing app booms, AI wins grammy, and more.
News from January 30 - February 6, 2025
DeepSeek Founder Hailed as Hero
DeepSeek founder Liang Wenfeng, already a billionaire at 40 from his hedge fund High-Flyer, received a hero's welcome when returning to China's Guangdong province for Lunar New Year.
His company's breakthrough showing that advanced AI can work with fewer high-end computer chips carries special weight in China, which faces restrictions on accessing top technology.
Despite his celebrated status, Wenfeng maintains a low profile, likely mindful of other Chinese tech leaders like Jack Ma and Pony Ma who faced government scrutiny after gaining too much public visibility.
Copycat Investing App Booms
Social media investing app Dub, founded by 23-year-old Harvard dropout Steven Wang, is revolutionizing trading by letting users copy top investors' portfolios with a single tap. The platform, which charges $10 monthly and takes a 25% cut of premium portfolio fees, has attracted 800,000 downloads and raised $17 million in seed funding.
While critics argue against active trading, Wang defends his TikTok-meets-Wall-Street approach. Among the platform's standout successes is a portfolio mirroring Nancy Pelosi's trades, up 123% since launch.
Steven Wang, Dub CEO: "We've been really lucky where the broader American population really believes there are other people out there that have an edge over them."
Obesity Drug Sales Surge
Danish drugmaker Novo Nordisk exceeded revenue expectations with $40 billion in 2024, up 26% from last year, powered by its obesity drug Wegovy's 50% sales increase. Despite outperforming analyst forecasts, the company projects slower growth of 16-24% for 2025.
The company's shares dropped 40% since June amid market doubts about obesity drug potential and specialist drugmaker valuations. This decline briefly cost Novo its position as Europe's largest company to LVMH in January.
Recent developments show mixed results: disappointing trial data for CagriSema wiped $90 billion off market value, while positive early results for another obesity drug, amycretin, boosted shares by 13%.
Disclaimer: This blog offers insights into international business and global events for informational purposes only. It is not intended as investment or business advice. WeavePay is not liable for any decisions made based on the content provided.We're on a mission to partner with ambitious international businesses. If your team has the vision and meets the criteria, join us at WeavePay for tailored payment solutions that have helped hundreds of global companies succeed in the complex global market. Subscribe and reach out to see if we're a match.